ALBION FINANCIAL GROUP /UT - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
ALBION FINANCIAL GROUP /UT ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$3,591
-16.3%
3,0430.0%0.00%
Q2 2023$4,291
-6.0%
3,0430.0%0.00%
Q1 2023$4,565
+28.2%
3,0430.0%0.00%
Q4 2022$3,560
+18.7%
3,0430.0%0.00%
Q3 2022$3,000
-40.0%
3,0430.0%0.00%
Q2 2022$5,0000.0%3,0430.0%0.00%
Q1 2022$5,000
-28.6%
3,0430.0%0.00%
-100.0%
Q4 2021$7,000
-12.5%
3,0430.0%0.00%0.0%
Q3 2021$8,000
-11.1%
3,0430.0%0.00%0.0%
Q2 2021$9,000
+80.0%
3,0430.0%0.00%
Q4 2020$5,0003,0430.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders